SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 3)*

Myovant Sciences Ltd.

(Name of Issuer)

Common Shares, \$0.000017727 par value per share (Title of Class of Securities)

> G637AM102 (CUSIP Number)

Seok Oh 1 Circle Star Way, San Carlos, California 94070 (650) 562-8202 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

> July 10, 2019 (Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Page 1 of 7

1

1.	Name of	Rep	orting Persons		
			ents (UK) Limited		
2.			propriate Box if a Member of a Group (see instructions)		
	(a) 🗆	(b)			
3.	B. SEC USE ONLY				
4. Source of Funds (see instructions)			nds (see instructions)		
		DO - other			
5.	Check if	Disc	losure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	hip oi	Place of Organization		
	England	and V			
		7.	Sole Voting Power		
	nber of		0		
	hares	8.	Shared Voting Power		
	eficially ned by				
	Each		0		
	oorting	9.	Sole Dispositive Power		
	erson				
	Nith		0		
		10.	Shared Dispositive Power		
			0 (see Item 5)		
11.	Aggrega	te Ar	nount Beneficially Owned by Each Reporting Person		
	0 (see Ite				
12.	Check if	the A	Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)		
13. Percent of Class Represented by A		of Cla	ass Represented by Amount in Row 11		
	0.0% (It	em 5)			
14.	Type of 2	Repo	rting Person (see instructions)		
	CO				

Page 2 of 7

r				
1.	Name of Reporting Persons			
			s (UK) LLP	
2.			propriate Box if a Member of a Group (see instructions)	
	(a) 🗆	(b)		
3.	SEC US	E ON	ILY	
4.	Source o	ource of Funds (see instructions)		
	OO - oth	er		
5.			losure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.		າເກ ດາ	Place of Organization	
0.	Gittibenio			
	England	and V	Wales	
	Lingitund	7.		
		<i>.</i> .		
Nur	mber of		0	
S	hares	8.	Shared Voting Power	
Ben	eficially	0.		
Ow	ned by		0	
I	Each	9.	Sole Dispositive Power	
	porting	9.	Sole Dispositive Power	
	erson		0	
I	With	10	Shared Dispositive Power	
		10.	Shared Dispositive Power	
11	A		0 (see Item 5)	
11.	Aggrega	te Ar	nount Beneficially Owned by Each Reporting Person	
	0 (I+-	F)		
10	0 (see Ite			
12.	Спеск 11	the F	Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)	
	_			
10				
13.	Percent o	ot Cla	ass Represented by Amount in Row 11	
	0.00/ (7	_`		
	0.0% (Ite			
14.	Type of 1	Repo	rting Person (see instructions)	
	PN			

Page 3 of 7

1.	Name of	Repo	orting Persons		
	SoftBan	k Visi	ion Fund L.P.		
2.			propriate Box if a Member of a Group (see instructions)		
	(a) 🗆	 ۲) 🛛		
	(u) <u></u>	(0)			
3.	SEC US				
5.	3EC 03	LON			
	0	6.55			
4.	Source o	ource of Funds (see instructions)			
		OO - other			
5.	Check if	Disc	losure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	nip oi	Place of Organization		
	Jersey				
	Ū	7.	Sole Voting Power		
		-			
Nur	nber of		0		
S	hares	8.	Shared Voting Power		
Ben	eficially	0.	Shared voting rower		
Ow	ned by		0		
H	Each	0			
Rej	oorting	9.	Sole Dispositive Power		
P	erson				
I	Nith		0		
		10.	Shared Dispositive Power		
			0 (see Item 5)		
11.	Aggrega	te Ar	nount Beneficially Owned by Each Reporting Person		
	0 (see Ite				
12.	Check if	the A	Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)		
13.	Percent	of Cla	ass Represented by Amount in Row 11		
			······································		
	0.0% (Ite	-m 5)			
14.			rting Person (see instructions)		
14.	Type of	керо	iung reison (see instructions)		
	DM				
	PN				

Page 4 of 7

1.	Name of	Repo	orting Persons		
	SVF GP	(Jers	ey) Limited		
2.			propriate Box if a Member of a Group (see instructions)		
	(a) 🗆	(b)			
3.	SEC US				
5.	5LC 05				
4. Source of Funds (see instructions)			ius (see instructions)		
		OO - other			
5.	Check if	Disc	losure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
	_				
6.	Citizens	nip oi	Place of Organization		
	Jersey				
		7.	Sole Voting Power		
	nber of		0		
	hares	8.	Shared Voting Power		
	eficially				
	ned by		0		
	Each	9.	Sole Dispositive Power		
	porting	5.			
	erson		0		
۱ I	Nith	10.	Shared Dispositive Power		
		10.	Shared Dispositive Power		
			0 (see Item 5)		
44	A				
11.	Aggrega	te Ar	nount Beneficially Owned by Each Reporting Person		
	0 (T	->			
15	0 (see Ite				
12.	Check if	the A	Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)		
	_				
13.	Percent	of Cla	ass Represented by Amount in Row 11		
	0.0% (It				
14.	Type of 1	Repo	rting Person (see instructions)		
		-			
	CO				

Page 5 of 7

INTRODUCTORY NOTE

Pursuant to Rule 13d-2 under the U.S. Securities Exchange Act of 1934, as amended (the "Act"), this Amendment No. 3 (the "Amendment") amends and supplements certain items of the Schedule 13D for the common shares, \$0.000017727 par value (the "Common Shares"), of Myovant Sciences Ltd., a Bermuda company (the "Issuer"), filed with the U.S. Securities and Exchange Commission (the "SEC") on September 15, 2017, as amended by Amendment No. 1 thereto filed with the SEC on April 4, 2018, and Amendment No. 2 thereto filed with the SEC on June 5, 2019 (as so amended, the "Original Schedule 13D"). This Amendment is filed by SVF Investments (UK) Limited, a limited company organized under the laws of England and Wales ("SVF Investments"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP, a limited liability partnership organized under the laws of England and Wales ("SVF Holdings"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P., a limited partnership organized under the laws of Jersey ("SoftBank Vision Fund"). This Amendment is also filed by SVF GP (Jersey) Limited, a limited company organized under the laws of Jersey and the general partner of Softbank Vision Fund ("SVF GP" and, together with the SVF Investments, SVF Holdings and SoftBank Vision Fund, the "Reporting Persons").

This Amendment constitutes an exit filing for the Reporting Persons. Due to changes in the internal governance of Roivant Sciences Ltd. ("Roivant") relating to Roivant's dispositive power over the Common Shares, the Reporting Persons are no longer deemed to beneficially own the Common Shares directly owned by Roivant. Additionally, based on other changes in Roivant's internal governance relating to oversight of Roivant's business and governance, the Reporting Persons are no longer deemed to control Roivant within the meaning of Instruction C to Schedule 13D. Roivant's ownership of the Issuer's Common Shares remains unchanged and this filing is not being made as a result of the purchase or sale of Common Shares of the Issuer by any party, including the Reporting Persons. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated as follows:

The information contained on each of the cover pages of this Schedule 13D and set forth or incorporated in Items 2, 3, 4 and 6 is hereby incorporated herein by reference.

- (a)–(b) None of the Reporting Persons have beneficial ownership of any Common Shares.
- (c) The reported share amounts for the Reporting Persons reflect amounts as of the date hereof. The Reporting Persons have not effected any transactions in the Common Shares since the filing of Amendment No. 2 of this Schedule 13D filed with the SEC on June 5, 2019.
- (d) Not applicable.
- (e) On July 10, 2019, the Reporting Persons ceased to be the beneficial owners of more than 5% of the Issuer's Common Shares.

Page 6 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 12, 2019

SVF INVESTMENTS (UK) LIMITED

By:	/s/ Karen Ubell
Name:	Karen Ubell
Title:	Attorney-in-Fact

SVF HOLDINGS (UK) LLP

By: SOFTBANK VISION FUND L.P., its Managing Member

By: SVF GP (JERSEY) LIMITED, its General Partner

By: /s/ Karen Ubell Name: Karen Ubell

Title: Attorney-in-Fact

SOFTBANK VISION FUND L.P.

By: SVF GP (JERSEY) LIMITED, its General Partner

By: /s/ Karen Ubell

Name: Karen Ubell Title: Attorney-in-Fact

SVF GP (JERSEY) LIMITED

By:	/s/ Karen Ubell
Name:	Karen Ubell
Title:	Attorney-in-Fact

Page 7 of 7